Skip to main content
. Author manuscript; available in PMC: 2016 Feb 23.
Published in final edited form as: Vaccine. 2015 Sep 15;33(42):5553–5563. doi: 10.1016/j.vaccine.2015.09.005

Fig. 2. Vaccine-induced Protection against HPV16 PsV challenge in the cervicovaginal mouse challenge model.

Fig. 2

Mice that were vaccinated with the various antigen and antigen-adjuvanted preparations described in Fig. 1 were divided into two groups and challenged either 2 weeks (A) or 19 weeks (B) after the final booster vaccination (see Supplementary Fig. S2). The readout for infection was recorded as bioluminescence signals as described in Section 2 and plotted for individual mice (●) in each group. Median and interquartile range values for each group are represented as horizontal bars.